Dentsply Sirona (XRAY) director amends Form 4 to show share purchase

Rhea-AI Filing Summary

DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky filed an amended insider report clarifying that a recent transaction was an open-market stock purchase. On this amended Form 4, he is shown buying 10,000 shares of common stock at $10.14 per share. Following this transaction, his direct ownership stands at 61,668.534 shares of DENTSPLY SIRONA common stock. The amendment corrects the original coding of the trade, which had been mistakenly reported as an award rather than a market purchase, while leaving all other details unchanged.

Insider Trade Summary

Net Buyer: 10,000 shares ($101,400)

Net Buy 1 txn

Insider MAZELSKY JONATHAN JAY

Role null

Bought 10,000 shs ($101K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$10.14	$101K

Holdings After Transaction: Common Stock — 61,668.534 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 10,000 shares Purchase price: $10.14 per share Shares owned after transaction: 61,668.534 shares +1 more

4 metrics

Shares purchased 10,000 shares Open-market purchase on 2026-06-12

Purchase price $10.14 per share Open-market transaction

Shares owned after transaction 61,668.534 shares Direct holdings following purchase

Net buy shares 10,000 shares Net change in share count in this filing

Key Terms

open market purchase, transaction code, Form 4, amendment

4 terms

open market purchase financial

"The correct transaction code is P, which reflects that the transaction was an open market purchase."

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

transaction code regulatory

"The transaction was inadvertently reported using transaction code A. The correct transaction code is P."

Form 4 regulatory

"This amendment is being filed to correct the transaction code reported in Table I of the original Form 4 filed on June 15, 2026."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

amendment regulatory

"This amendment is being filed to correct the transaction code reported in Table I of the original Form 4."

An amendment is a formal change or addition to an existing legal, regulatory, or corporate document, such as a contract, prospectus, regulatory filing, or company charter. It matters to investors because amendments can alter rights, deadlines, obligations, or risk profiles tied to an investment; think of it like editing a recipe—changing an ingredient or cooking time can significantly affect the final result.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 06:24 PM Accepted by SEC EDGAR 06/18/2026 - 06:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAZELSKY JONATHAN JAY

(Last) (First) (Middle)

C/O DENTSPLY SIRONA INC

13320-B BALLANTYNE CORPORATE PLACE

(Street)

CHARLOTTE NORTH CAROLINA 28277

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DENTSPLY SIRONA Inc. [ XRAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/15/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		P(1)		10,000	A	$10.14	61,668.534	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment is being filed to correct the transaction code reported in Table I of the original Form 4 filed on June 15, 2026. The transaction was inadvertently reported using transaction code A. The correct transaction code is P, which reflects that the transaction was an open market purchase. All other information in the original filing remains unchanged.

	/s/ Jessica Nielsen Causey, Attorney-in-Fact for Jonathan Jay Mazelsky	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did DENTSPLY SIRONA (XRAY) report in this Form 4/A?

The filing shows director Jonathan Jay Mazelsky executed an open-market purchase of 10,000 shares of DENTSPLY SIRONA common stock. This was reported as a routine insider buy at a specific per-share price.

At what price did the DENTSPLY SIRONA (XRAY) director buy shares?

The director bought 10,000 common shares at $10.14 per share. This price reflects an open-market purchase and represents a total cash outlay of roughly $100,000 before any transaction costs.

How many DENTSPLY SIRONA (XRAY) shares does the insider hold after this transaction?

After the reported purchase, Jonathan Jay Mazelsky directly owns 61,668.534 DENTSPLY SIRONA common shares. This total reflects his position immediately following the 10,000-share open-market acquisition disclosed in the amended Form 4.

Why was this DENTSPLY SIRONA (XRAY) Form 4/A filed as an amendment?

The amendment corrects the transaction code originally used for the trade. The transaction was first reported as code A but is now correctly identified as code P, indicating an open-market purchase rather than an award.

Does the DENTSPLY SIRONA (XRAY) Form 4/A change any details besides the transaction code?

The amendment only updates the transaction code to P for an open-market purchase. According to the disclosure, all other information from the original Form 4, including share amount, price, and holdings, remains unchanged.